Kang DY, et al. - In this randomized, multicenter, prospective trial enrolling 302 patients with very long (≥50 mm) native coronary lesions, researchers compared in-segment late luminal loss at 12-month angiographic follow-up between patients treated with Resolute zotarolimus-eluting stents (R-ZES) vs Xience everolimus-eluting stents (EES). Fifty percent of eligible patients were followed-up. Similar baseline features were noted in the R-ZES and EES groups, with lesion length of 49.6±10.2 and 50.6±13.3 mm, respectively (P=0.47). Findings demonstrated comparable angiographic and clinical outcomes (in-segment late luminal loss, in-segment binary restenosis rates, and rate of adverse events) with R-ZES and EES implantation, as observed over 1 year of follow-up in patients treated for very long native coronary artery disease.